Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anaptysbio (ANAB) Other Non-Current Liabilities (2016 - 2025)

Anaptysbio's Other Non-Current Liabilities history spans 9 years, with the latest figure at $276.5 million for Q4 2025.

  • For Q4 2025, Other Non-Current Liabilities fell 21.76% year-over-year to $276.5 million; the TTM value through Dec 2025 reached $276.5 million, down 21.76%, while the annual FY2025 figure was $276.5 million, 21.76% down from the prior year.
  • Other Non-Current Liabilities reached $276.5 million in Q4 2025 per ANAB's latest filing, down from $331.8 million in the prior quarter.
  • In the past five years, Other Non-Current Liabilities ranged from a high of $362.0 million in Q2 2024 to a low of $35.0 million in Q3 2022.
  • Average Other Non-Current Liabilities over 5 years is $293.7 million, with a median of $310.2 million recorded in 2024.
  • Peak YoY movement for Other Non-Current Liabilities: skyrocketed 789.35% in 2023, then fell 21.76% in 2025.
  • A 5-year view of Other Non-Current Liabilities shows it stood at $251.1 million in 2021, then increased by 21.24% to $304.4 million in 2022, then increased by 2.1% to $310.8 million in 2023, then rose by 13.71% to $353.4 million in 2024, then fell by 21.76% to $276.5 million in 2025.
  • Per Business Quant, the three most recent readings for ANAB's Other Non-Current Liabilities are $276.5 million (Q4 2025), $331.8 million (Q3 2025), and $331.4 million (Q2 2025).